Home > Insider Trading > Filing (0001181431-12-037304)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
897448	Amarin Corp Plc	AMRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1511459	Paul Huff	C/O Amarin Pharma, Inc. 1430 Route 206, Suite 200 Bedminster NJ 07921	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2012-06-15	100	$8.79	100	No	4	M	Direct
Ordinary Shares	Disposition	2012-06-15	100	$12.00	0	No	4	S	Direct
Ordinary Shares	Acquisiton	2012-06-18	162,925	$8.79	162,925	No	4	M	Direct
Ordinary Shares	Disposition	2012-06-18	162,925	$12.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (right to buy)	Disposition	2012-06-15	100	$0.00	100	$8.79
Ordinary Shares	Stock Option (right to buy)	Disposition	2012-06-18	162,925	$0.00	162,925	$8.79

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
887,925		2021-01-28	No	4	M	Direct
725,000		2021-01-28	No	4	M	Direct

Footnotes

On January 28, 2011, the reporting person was granted an option under the Amarin Corporation plc 2002 Stock Option Plan. The stock option vests in four equal installments on each anniversary of such grant date.
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2012.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.